Молекулярно-генетический мониторинг минимальной остаточной болезни у пациентов с хроническим миелолейкозом
Диссертация
Моноклональные реаранжировки Т-клеточного рецептора у больных XMJI не является редкостью и отражают степень вовлеченности лимфоидного ростка в патогенез XMJI. Несмотря на отсутствие прямых статистических корреляций между наличием или отсутствием BCR-ABL и «моно-» или поликлональностью Т-клеточного рецептора гамма-дельта, последний может использоваться в качестве дополнительного критерия оценки… Читать ещё >
Список литературы
- Богданов К.В., Фролова О. И., Марннец О. В. и др. Клиническое значение вариантов хромосомной транслокации t(9−22) у больных хроническими миелолейкозами // Гематол. и трансфузиол.-2003.-№ 3,-С.3−9.
- Боровиков В.П., Боровиков И. П. Введение в программу Statistica // М.: КомпьютерПресс, 1997.-С.20−35.
- Волкова М.А. Гливек революция в терапии хронического миелолейкоза // Онкология.-2003.-№ 14.-С.4−9.
- Глянц С. Медико-биологическая статистика // Пер. с анг. д. ф-м.н. Данилова Ю.А.-М.: «Практика».-1999.-424 с.
- Закс Л. Статистическое оценивание // Пер. с нем. Варыгина В.Н.- М.: «Статистика».-1976.-598 с.
- Клаус Дж. Лимфоциты. Методы. М.: Мир.-1990.-С52−53.
- Петухов В.Н., Строжа И. Л., Жиличев A.B. и др. Эффективность альфа-интерферонотерапии и bcr-abl транскрипты у больных хроническим миелолейкозом // Гематол. и трансфузиол.-1999.-Т.44.,№ 1.-С.З-6.
- Шизон К. Хронический миелолейкоз у детей // Гематол. и трансфузиол.-1998.-Т.43 .-С.22−24.
- Яворковский Л.И. Полимеразная цепная реакция в диагностике онкогематологических заболеваний // Эксп. Онкология.-1991.-Т. 13.-С.3−7.
- Aldous W К, Marean A J, DeHart М J. et al. Fluorescent detection of telomerase activity // Methods Mol Biol.-2002.-Vol.191.-P. 137−146.
- Amikam D., Henig C., Carter A. et al. A correlation between the expression of the bcr-abl chimeric gene and severity of the clinical state of CML patients with time // Scand. J. Immunol.-1995.-Vol.41.-P.529−533.
- Becker K, Pan D, Whitley С В. Real-time quantitative polymerase chain reaction to assess gene transfer // Hum Gene Ther.-1999.-Vol.10.-P.2559−2566. t
- Bhatia R., Mc Carthy J.B., Verfaillie C.M. Interferon-alfa restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia // Blood.-1996.-Vol.87.-P.3883−3891.
- Biernaux C., Loos M., Sele A. et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthly individuals // Blood.-1995.-Vol.8.-P.3118−3122.
- Bock O, Serinsoz E, Schlue J. et al. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases // Leuk Research.-2004.-Vol.28.-P.457−460.
- Brunori M, Luciano P, Gilson E. et al. The telomerase cycle: normal and pathological aspects // J Mol Med.-2005.-Vol.83.-P.244−257.
- Campanini F, Santucci MA, Pattachini L. et al. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia // Haematologica.-2001.-Vol.86.-P.167−173.
- Cerione R. and Zheng Y. The Dbl family of oncogenes // Curr. Opin. Cell. Biol.-1996.-Vol. 8 .-P.216−222.
- Coccoris M, de Witte M A, Schumacher T N. Prospects and limitations of T cell receptor gene therapy // Curr Gene Ther.-2005.-Vol.5.-P.583−593.
- Colombat M, Fort MP, Chollet C. et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment // Haematologica.-2006.-Vol.91.-P.162−168.
- Cortes D., Stoica G., Pierce J.H. et al. The Bcr-Abl tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway // Oncogene.1996.-Vol. 13 .-P.2589−2594.
- Cortes J.E., Talpaz M., Beran M. et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results // Cancer.-1995.-Vol.75.-P.464−470.
- Cwynarski K., Roberts I., Iakobelli S. et al. Stem cell transplantation for chronic myeloid leukemia in children // Blood.-2003. V.78,-P.1428−1431.
- Double JA. Telomerase as a therapeutic target. Therapeutic potential of telomerase inhibitors //Methods Mol Biol.-2002.-Vol.l91.-P.209−216.
- Drobyski W R, Hessner M J. The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia // Leuk Lymphoma.-1998.-Vol.31.-P.317−323.
- Goldman G. and Draker B.J. Chronic myeloid leukemia: current treatment options // Blood.-2001.- Vol.98, № 7.-P.2039−2042.
- Hasford J., Pfirrmann M., Hehlmann R. et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferonalfa // J. Natl. Cancer Institute.- 1998.-Vol.90, № 11.-P.850−858.
- Hilbe W, Kuhr T, Apfelbeck U. et al. Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C // Leuk Lymphoma.-2001.-Vol.42.-P. 1283−1288.
- Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia // Acta Haematol.-2002.-Vol. 107.-P.76−94.
- Kantaryjian H., Sawyers C., Hochhaus A. et al. Hematological and cytogenetic responses to Imatinib Mesylat in chronic myeloid leukemia // New. Engl. J. Med.-2002.- Vol.346, № 9.-P.645−652.
- Langabeer SE, Gale RE, Harvey RC. et al. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABLtranscript levels in patients with chronic myeloid leukaemia // Leukemia.-2002.-Vol.l6.-P.393−399.
- Lee S J. Chronic myelogenous leukaemia // Br J Haematol.-2000.-Vol. 111.-P.993−1009.
- Levis I.D., Haylock D.N., Moore S. et al. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia // Leukemia.-1997.-Vol.l 1 .-P.581−587.
- Lipton J H, Derzko C M, Curtis J. Alpha-interferon and pregnancy in a patient with CML // Hematol Oncol.-1996.-Vol.l4.-P.l 19−122.
- Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib // Leuk Lymphoma.-2004.-Vol.45.-P.2197−2203.
- Lukasova E., Kozubek S., Kozubek M. et al. Localization and distance between Abl and Bcr genes in interphase nuclei of bone marrow cells of control donors and patients with chronic myeloid leukemia // Human Genetics.-1997.-Vol.l00.-P.525−535.
- Macera MJ., Smith L.J., Frankel E. et al. A philadelphia negative chronic myelogenous leukemia with chimeric bcr-abl gene on chromosome 9 and b3a2 splice junction//Cancer. Genet. Cytogenet.-1998.-Vol.l01.-P.143−147.
- Mauro M J, Druker B J. Chronic myelogenous leukemia // Curr Opin 0ncol.-2001 .-Vol. 13 .-P.3−7.
- Mei Y P, Zhu X F, Zhou J M. et al. siRNA targeting LMPl-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression // Cancer Lett.-2006.-Vol.232.-P.189−198.
- Miyamura T. Interaction of bcr-abl with the retinoblastoma protein in philadelphia chromosome-positive cell lines // Int. J. Hematol.-1997--Vol.62.-P.l 15−121.
- Nanjangud G J, Saikia TK, Chopra H. et al. Development of Ph positive chronic myeloid leukemia in a patient with chronic lymphocytic leukemia treated with total body irradiation: a rare association // Leuk Lymphoma.-1996.-Vol.22.-P.355−3 59.
- Osborne T. Accurate urine telomerase test for detecting bladder cancer // Nat Clin Pract Oncol.-2006.-Vol.3.-P.69. ^
- Pasternak G., Hochhaus A., Schltheis B. et al. Chronic myelogenous leukemia: molecular and cellular aspects // J. Cancer Res. Clin. Oncol.-1998.-Vol.l2.-P.643−660.
- Pear W.S., Miller J.P., Xu L. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr-abl-transduced bone marrow // Blood.-1998.-Vol.92.-P.3780−3792.
- Peggs K., Mackinnon S. Imatinib Mesylat the new gold standard for treatment of chronic myeloid leukemia // New. Engl. J. Med.-2003.- V.348, № 11.-P. 1048−1050.
- Pelz A F, Kroning H, Franke A. et al. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements // Ann Hematol.-2002.-Vol.81 .-P. 147−153.
- Pendergast A.M. Nuclear tyrosine kinases: from Abl to Wee 1 // Curr. Opin. Cell. Biol.-1996.-Vol.8.-P. 174−181.
- Posthuma E.F.M., de Paus R., Kluin-Nelemans H. et al. The b3a2 junction type of the bcr-abl oncogene is a favorable prognostic factor for a complete response to interferon treatment in patients with chronic myeloid leukemia
- CML) 11 Chronic Myeloid Leukemia molecular and biological studies. Simposium.-1999.-Abstract # 378.
- Prowse KR. Detection of telomerase activity in neural cells // Methods Mol Biol.-2002.-Vol. 198.-P. 137−147.
- Rasoul N A, Elhalawani N, Nafae M H. et al. Telomerase activity in Philadelphia positive chronic myeloid leukaemia // Egypt J Immunol.-2004.-Vol.ll.-P.l-8.
- Reiffers J., Mahon F.X., Boiron J.M. et al. Autografting in chronic myeloid leukemia: an overview // Leukemia.-1996.-Vol.l0.-P.385−388.
- Rozman C., Urbano-Ispizua A., Cervantes F. et al. Analysis of the clinical relevance of the breakpoint location within M-bcr and the type of chimeric mRNA in chronic myelogenous leukemia // Leukemia.-1995.-Vol.9.1. P. l 104−1107. (
- Saffroy R, Lemoine A, Brezillon P. et al. Real-time quantitation of bcr-abl transcripts in haematological malignancies // Eur. J. Haematol.-2000.-Vol.65.-P.258−266.
- Saglia G. Consistent amounts of acute leukemia-associated pi 90 bcr-abl transcripts are expressed by CML patients at diagnosis // Blood.-1996.-Vol.87.-P. 1075−1080.
- Saglio G. Minimal residual disease detection in human leukemias: biologic and clinical significance // Acta Haematol Pol.-1995.-Vol.26.-P.19−24.
- Salgia R., Li J., Ewaniuk D.S. et al. Bcr-Abl induces multiple abnormalities, of cytoskeletal function//J. Clin. Invest.-1997.-Vol.l00.-P.46−57.
- Salgia R., Pisick E., Sattler M. et al. pi30 Cas forms a signaling complex with the adapter protein Crkl in hematopoietic cells transformed by the Bcr-Abl oncogene // J. Biol. Chem.-1996.-Vol.271.-P.25 198−25 203.
- Savage D., Antman K. Imatinib Mesylat a new oral targeted therapy //
- Cancer Res.-2005.-Vol.65.-P.3513−3517. 82. Shuai K, Halpern J, ten Hoeve J. et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia // Oncogene.1996.-Vol. 13 .-P.247−254.
- Smit M L, Giesendorf B A, Vet J A. et al. Semiautomated DNA mutation analysis using a robotic workstation and molecular beacons // Clin Chem.-2001.-Vol.47.-P.739−744. *
- Storlazzi C T, Anelli L, Surace C. et al. Molecular cytogeneticcharacterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia // Cancer Genet Cytogenet.-2002.-Vol. 13 6.-P. 141 -145.
- Tauchi T., Miyazawa K., Feng G.S. et al. Bcr-Abl is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome-positive leukemia // Biol. Chem.1997.-Vol.272.-P. 13 89−1394.
- Tennant L. Chronic myelogenous leukemia: an overview // Clin J. Oncol Nurs.-2001 .-Vol.5 .-P.218−219.
- Trepel M., Scheding S., Groscurth P. et al. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy // Leukemia.-1997.-Vol. 11.1. P. 1842−1849.Q
- Van, Dongen J., Szczepanski T., De Bruijn M. et al. Detection of minimal residual disease in acute leukemia patients // Cytokines and Molecular Therapy.-1996.-Vol.2.-P. 121−133.
- Vulliamy T J, Walne A, Baskaradas A. et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure // Blood Cells Mol. Dis.-2005.-Vol.34.-P.257−263.
- Welch P.J. and Wang J.Y.J. Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and independent mechanisms // Mol. Cell. Biol.-1995.-Vol. 15.-P.5542−5551.
- Wen X., Lin H.H., Shih H.J. et al. Kinase activation of nonreceptor tyrosine kinase is sufficient to transactivate STAT-mediated gene expression* in salivary and lung epithelial cell // J. Biol. Chem.-1999.-Vol.274.-P.38 204−308 210.
- Yamagata T, Mitani K, Kanda Y. et al. Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia // Br. J. Haematol.-1996.-Vol.94.-P.370−372.